clinical trial · NCT07055321
A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants
Healthy SubjectsETH47ETH47ETH47ETH47ETH47ETH47ETH47ETH47
brief summary
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and target engagement of ETH47 in healthy participants following single intranasal and single inhaled administration
started
Nov 29, 2023
primary completion
Jul 8, 2024
completion
Jul 8, 2024
last updated
Jul 8, 2025
official title
A Phase 1, First-in-human, Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol